Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05421416 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Loratadine for the Prevention of G-CSF-related Bone Pain

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv6
  2. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Nov 1, 2026 to Dec 1, 2026
    • Start date changed from estimate of Oct 1, 2024 to Nov 28, 2024
    • Site details revised
    v5
  3. Start date: Apr 1, 2024 to Oct 1, 2024v4
  4. Primary completion date: Nov 1, 2024 to Nov 1, 2026
    • Start date: Nov 1, 2023 to Apr 1, 2024
    • Study completion date: Nov 1, 2025 to Nov 1, 2026
    v3
  5. Start date: Nov 1, 2022 to Nov 1, 2023v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The research question for the current study is: Is loratadine more effective than placebo in preventing G-CSF-related bone pain during autologous hematopoetic stem cell transplant in patients with lymphoma or multiple myeloma? The hypothesis is that prophylaxis with loratadine will help prevent or reduce the severity of bone pain in this setting.
Trial Details
NCT Number NCT05421416
Lead Sponsor AHS Cancer Control Alberta
Conditions
(from sponsor)		 Stem Cell Transplant Complications
Enrollment 78 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov